Ardelyx (ARDX) Assets Average (2014 - 2026)
Ardelyx's (ARDX) quarterly Assets Average came in at $503.1 million in Q1 2026, up 18.93% YoY from $423.0 million in Q1 2025, and up 1.86% on a QoQ basis from $493.9 million in Q4 2025.
Ardelyx (ARDX) Assets Average (2014 - 2026) Analysis & Trends
Ardelyx (ARDX) has 13 years of Assets Average data on file, last reported at $503.1 million in Q1 2026.
- Quarterly Assets Average rose 18.93% year-over-year to $503.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $503.1 million (up 18.93% YoY) and the FY2025 annual result came in at $468.7 million, up 27.82% from the prior year.
- Assets Average rose to $503.1 million in Q1 2026, from $493.9 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $503.1 million in Q1 2026 to a low of $130.5 million in Q2 2022.
- A 5-year average of $311.3 million and a median of $320.0 million in 2024 frame the typical range for Assets Average.
- Annual changes were most pronounced in 2022 — Assets Average slumped 37.15% — and 2023, when it jumped 81.19%.
- Tracing ARDX's Assets Average over 5 years: stood at $167.4 million in 2022, then surged by 75.35% to $293.5 million in 2023, then soared by 36.91% to $401.8 million in 2024, then increased by 22.92% to $493.9 million in 2025, then advanced by 1.86% to $503.1 million in 2026.
- The last three Assets Average figures came in at $503.1 million (Q1 2026), $493.9 million (Q4 2025), and $476.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Ardelyx | 1.01 Bn | 729.71 Mn | 115.12 Mn | 540.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 540.20 Mn |
| Mar 31, 2026 | 503.06 Mn |
| Dec 31, 2025 | 493.89 Mn |
| Sep 30, 2025 | 476.47 Mn |
| Jun 30, 2025 | 438.48 Mn |
| Mar 31, 2025 | 422.97 Mn |
| Dec 31, 2024 | 401.81 Mn |
| Sep 30, 2024 | 355.68 Mn |
| Jun 30, 2024 | 342.94 Mn |
| Mar 31, 2024 | 319.98 Mn |
| Dec 31, 2023 | 293.48 Mn |
| Sep 30, 2023 | 250.29 Mn |
| Jun 30, 2023 | 214.11 Mn |
| Mar 31, 2023 | 203.54 Mn |
| Dec 31, 2022 | 167.37 Mn |
| Sep 30, 2022 | 138.14 Mn |
| Jun 30, 2022 | 130.51 Mn |
| Mar 31, 2022 | 139.66 Mn |
| Dec 31, 2021 | 160.38 Mn |
| Sep 30, 2021 | 187.92 Mn |